Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Ankit Agrawal *Center for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute Cleveland Clinic Cleveland OH.ORCID 0000-0001-7885-6667
Akiva Rosenzveig *Center for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute Cleveland Clinic Cleveland OH.ORCID 0000-0001-6757-8841
Ahmad SafdarCenter for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute Cleveland Clinic Cleveland OH.
Danial NasifCenter for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute Cleveland Clinic Cleveland OH.ORCID 0009-0000-3615-2610
Umesh BhagatCenter for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute Cleveland Clinic Cleveland OH.
Jibran IkramCenter for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute Cleveland Clinic Cleveland OH.ORCID 0009-0003-6653-0661
Muhammad EhsanCenter for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute Cleveland Clinic Cleveland OH.ORCID 0000-0002-6021-2342
Muhammad MajidCenter for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute Cleveland Clinic Cleveland OH.ORCID 0000-0002-9353-361X
Ashwin KumarCenter for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute Cleveland Clinic Cleveland OH.ORCID 0000-0003-3379-847X
Aro Daniela ArockiamCenter for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute Cleveland Clinic Cleveland OH.ORCID 0009-0004-9691-7258
Beni R VermaCenter for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute Cleveland Clinic Cleveland OH.
Julia WajsbergDepartment of Medicine University Hospitals Cleveland OH.
Allan L KleinCenter for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute Cleveland Clinic Cleveland OH.ORCID 0000-0001-9240-8369
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
backgroundImmune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but carry a risk of immune-related adverse events, reported in 15% to 90% of the patients. ICI-associated pericardial and myocardial disease has been increasingly recognized, yet data on outcomes remain limited. We aimed to use a large real-world database to investigate the short- and long-term outcomes of ICI-associated pericarditis, myocarditis, and myopericarditis versus the non-ICI cases.
methodsWe conducted a retrospective analysis using the TriNetX database to identify patients >18 years old on ICI and diagnosed with pericarditis, myocarditis, or myopericarditis within 1 year of initiation of therapy. The primary outcome assessed was all-cause mortality, tamponade, constrictive pericarditis, and need for pericardiocentesis at 90-day, 1-year, and 5-year follow-up.
resultsA total of 3661, 226, and 46 patients were identified in matched cohorts of ICI-induced pericarditis, myocarditis, and myopericarditis, respectively. One- and 5-year mortality was greater for pericarditis (44.3% versus 37.3%; 54.3% versus 46.9%), myocarditis (38.9% versus 20.8%; 47.8% versus 34.3%), and myopericarditis (56.5% versus 28.3%; 63.0% versus 28.3%; all
conclusionAmong 3661, 226, and 46 patients with ICI-associated pericarditis, myocarditis, and myopericarditis, respectively, we demonstrated an increased risk of all-cause mortality as compared with the respective non-ICI population.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Short- and Long-Term Outcomes of Pericarditis, Myocarditis, and Myopericarditis in Patients With Malignancy on Immune Checkpoint Inhibitors. · full record | OpenQuestion